Last reviewed · How we verify
Buprenorphine and Norbuprenorphine
At a glance
| Generic name | Buprenorphine and Norbuprenorphine |
|---|---|
| Sponsor | ViiV Healthcare |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Long-term Buprenorphine Plasma Exposure
- A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone (PHASE1)
- Norspan Transdermal Patches Study in Osteoarthritis Patients (PHASE1)
- TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Buprenorphine and Norbuprenorphine CI brief — competitive landscape report
- Buprenorphine and Norbuprenorphine updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI